F M Investments LLC Makes New Investment in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

F M Investments LLC purchased a new position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 42,004 shares of the biopharmaceutical company's stock, valued at approximately $1,767,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Raymond James Financial Inc. bought a new stake in Ultragenyx Pharmaceutical in the 4th quarter valued at about $916,000. Renaissance Technologies LLC increased its stake in shares of Ultragenyx Pharmaceutical by 39.9% in the fourth quarter. Renaissance Technologies LLC now owns 254,700 shares of the biopharmaceutical company's stock valued at $10,715,000 after purchasing an additional 72,600 shares during the period. Invesco Ltd. raised its holdings in shares of Ultragenyx Pharmaceutical by 1.5% during the fourth quarter. Invesco Ltd. now owns 1,699,756 shares of the biopharmaceutical company's stock valued at $71,509,000 after buying an additional 25,487 shares during the last quarter. ADAR1 Capital Management LLC acquired a new position in shares of Ultragenyx Pharmaceutical during the fourth quarter worth approximately $337,000. Finally, Aster Capital Management DIFC Ltd bought a new position in Ultragenyx Pharmaceutical in the 4th quarter worth approximately $35,000. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on RARE shares. JPMorgan Chase & Co. boosted their price target on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an "overweight" rating in a research report on Thursday, March 27th. HC Wainwright reaffirmed a "buy" rating and issued a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Friday, February 14th. Canaccord Genuity Group raised their target price on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a research note on Tuesday, February 18th. Wedbush reaffirmed a "neutral" rating and issued a $48.00 price target (up from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th. Finally, Piper Sandler lowered their price objective on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating on the stock in a research note on Monday, March 17th. One analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to MarketBeat, Ultragenyx Pharmaceutical currently has an average rating of "Moderate Buy" and a consensus target price of $92.79.

Ultragenyx Pharmaceutical Trading Up 1.7 %

Shares of NASDAQ RARE traded up $0.59 during mid-day trading on Thursday, reaching $35.57. The company had a trading volume of 191,881 shares, compared to its average volume of 806,468. The company has a 50-day moving average price of $38.75 and a two-hundred day moving average price of $44.54. The stock has a market cap of $3.34 billion, a PE ratio of -5.63 and a beta of 0.61. Ultragenyx Pharmaceutical Inc. has a 1-year low of $29.59 and a 1-year high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The firm had revenue of $164.88 million during the quarter, compared to analysts' expectations of $163.23 million. On average, research analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In related news, CAO Theodore Alan Huizenga sold 967 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total value of $40,710.70. Following the transaction, the chief accounting officer now owns 50,265 shares in the company, valued at approximately $2,116,156.50. This represents a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Karah Herdman Parschauer sold 2,990 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $42.88, for a total transaction of $128,211.20. Following the completion of the sale, the executive vice president now owns 54,991 shares of the company's stock, valued at $2,358,014.08. This trade represents a 5.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 124,643 shares of company stock valued at $5,256,268 in the last 90 days. 5.80% of the stock is currently owned by corporate insiders.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.